Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30 ...
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30 ...
Sanofi’s Admelog (insulin lispro) is approved in type 1 ... Approved at the beginning of 2016, US revenues of the cheaper competitor, Basaglar, were around $115 million in Q3, almost double ...
As of 10:39:37 GMT-4. Market open. Loading Chart for LLY ...
At close: March 19 at 1:59:39 PM CST Loading Chart for LLY.MX ...
After hours: 8:00:00 pm GMT-4 Loading Chart for LLY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback